Contineum Therapeutics, Inc. Class A CTNM 深 沪
已收盘 01-30 16:00:00 美东时间
14.26
-0.340
-2.33%
华盛通- 最 高14.94
- 今 开14.40
- 成交量 55.53万股
- 最 低 13.58
- 昨 收 14.60
- 总市值 4.16亿
- 52周最高 14.94
- 市盈率 静 --
- 换手率 1.90%
- 52周最低 3.35
- 委 比 -47.85%
- 总股本 2918.25万
- 历史最高 22.00
- 量 比 2.50
- 振 幅 9.32%
- 历史最低 3.35
- 每 手 1
- 风险率 3.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on T...
01-14 01:28
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Morgan Stanley Downgrades Contineum Therapeutics to Equal-Weight, Lowers Price Target to $14
Morgan Stanley analyst Jeffrey Hung downgrades Contineum Therapeutics (NASDAQ:CTNM) from Overweight to Equal-Weight and lowers the price target from $23 to $14.
01-08 20:19
Contineum Therapeutics shares are trading lower after the company announced a proposed $75 million public offering of Class A common shares.
Contineum Therapeutics shares are trading lower after the company announced a p...
2025-12-12 05:16
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
Market-Moving News for November 21st
CTNM: -20% | Contineum Therapeutics shares are trading lower after the company announced that topline data from its Phase 2 VISTA trial of PIPE-307 did not meet its primary or secondary efficacy
2025-11-21 20:16
Contineum Therapeutics shares are trading lower after the company announced that topline data from its Phase 2 VISTA trial of PIPE-307 did not meet its primary or secondary efficacy endpoints.
Contineum Therapeutics shares are trading lower after the company announced tha...
2025-11-21 05:36
Contineum Therapeutics Q3 EPS $(0.45) Beats $(0.60) Estimate
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.60) by 24.75 percent. This is a 12.5 percent decrease over losses of $(0.40) per share
2025-10-31 04:51
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
2025-09-26 09:45
